Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

Southwest Falls in Premarket; Meituan ADRs, Exxon Mobil Rise

Published 2021-10-11, 08:46 a/m
© Reuters.
MRK
-
XOM
-
LUV
-
EMR
-
HAS
-
CL
-
AZN
-
KKR
-

By Geoffrey Smith

Investing.com -- Stocks in focus in premarket trading on Monday, 11th October. Please refresh for updates

  • Southwest Airlines (NYSE:LUV) stock fell 2.6% after a heavily disrupted weekend for flight movements, as bad weather in Florida led to cascading problems of aircraft and personnel availability. The airline canceled over 1,000 flights on Sunday, or more than a quarter of its schedule. 
  • Aspen Tech stock rose 4.2% after Emerson (NYSE:EMR) Electric agreed to spin off its industrial software operations into the company in a deal aimed at creating a more full suite of services to large industrial customers. Emerson stock was unchanged, having traded down earlier in the premarket session
  • Hasbro (NASDAQ:HAS) stock fell 1.3% after the company announced that CEO Brian Goldner will take medical leave, with immediate effect. Rich Stoddart, the company's lead independent director, will take over the role of CEO on an interim basis. 
  • Meituan ADRs rose 4.7% to their highest in two and a half months after the company escaped largely unscathed from an antitrust probe. China's competition watchdog fined it $534 million for various abuses of a dominant position in the food delivery market. Other Chinese ADRs rose in sympathy, on hopes that the worst case scenario envisaged by some under Beijing's crackdown on tech companies can be avoided.
  • Exxon Mobil (NYSE:XOM) stock rose 1.5% to a three-month high as crude oil prices continued their ascent. U.S. crude futures hit a fresh seven-year high as trading in New York began, still supported by a sharp squeeze on gas and coal markets worldwide. 
  • AstraZeneca (NASDAQ:AZN) ADRs rose 0.6% after it reported promising trial results for an experimental antiviral drug for treating Covid-19. The company said the drug reduced the risk of serious illness by half in a trial a little larger than the one carried out by Merck (NYSE:MRK)for a similar drug.
  • Merck stock rose 0.6% after the pharma company formally requested emergency use authorization for its antiviral Covid-19 pill, which could become the first effective orally-administered drug against the coronavirus.
  • KKR  (NYSE:KKR) stock rose 0.8%, extending Friday's gains as the private equity giant's two remaining founders said they will step down and hand the reins to long-time company insiders.

 

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.